Maysa Vilbert

73 posts

Maysa Vilbert

Maysa Vilbert

@MaysaVilbert

Oncologist passionate about enhancing the lives of cancer survivors, advancing cancer research, and investigating immune toxicities.

Cambridge, USA Katılım Nisan 2021
1K Takip Edilen222 Takipçiler
Maysa Vilbert retweetledi
ASPIRE Community of Practice
ASPIRE Community of Practice@ASPIRE_CoP·
Check out this IRAE chapter in the #ASCO25 education book! Come attend the session on May 30th details ⬇️
Mazie Tsang, MD, MAS, MS@MazieTsangMD

@ASPIRE_CoP @ASCO @PGrivasMDPhD @FunchainMD @oncodaily @drteplinsky @KMittalmd @CheckpointNowMD Thank you so much, #ASPIRE! Our team is excited to highlight our ASCO Education Book chapter: ascopubs.org/doi/10.1200/ED…. The accompanying session is on May 30th!

English
0
2
5
426
Maysa Vilbert retweetledi
Ticiana Batista (Leal)
Ticiana Batista (Leal)@LealTiciana·
Thank you OncoDaily! Honored to be on the ballot for the 2025 @IASLC Board of Directors and look forward to the opportunity to expand optimal lung cancer care and clinical trials on a global scale. @RamalingamMD @IASLC @WinshipAtEmory
OncoDaily@oncodaily

Honored to announce my candidacy for the 2025 @IASLC Board of Directors - Ticiana Leal (@LealTiciana) oncodaily.com/blog/ticiana-l… #OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #IASLC

English
0
4
29
2.9K
Maysa Vilbert retweetledi
Pauline Funchain
Pauline Funchain@FunchainMD·
It’s a wrap for ASPirE ‘25! In medicine we continually see new challenges, face deadly obstacles, and wake up the next day to do it again. Sometimes in light. Sometimes dark. We give each other strength. Keep going fam. Keep going dear patients. Medicine perseveres. Love, ASPirE
Pauline Funchain tweet mediaPauline Funchain tweet mediaPauline Funchain tweet media
English
1
3
14
770
Maysa Vilbert retweetledi
Gabriela Gazzoni, MD
Gabriela Gazzoni, MD@GazzoniGabriela·
Check out poster board E23 🇧🇷 at #GU25 @ASCO We evaluated the incidence of skin reaction in EV mono in clinical trials and real-world data 📊 Incidence rate of all-grade skin reactions was 50% and about 10% in grade 3 or higher @MaysaVilbert @isabfmichelon @anacardosomd
Gabriela Gazzoni, MD tweet media
English
0
1
12
680
Maysa Vilbert retweetledi
Pauline Funchain
Pauline Funchain@FunchainMD·
Top of the irAE to you this Monday! 2 ASPirE events to kick off 2025: ASPirE Annual Meeting 2/28 - 3/1: in person think tank graciously hosted by @afreenshariffmd @dukemedicine ASPirE Webinar 3/10: Launch of our Tumor Board series hosted by Yinghong Mimi Wang @MDAndersonNews
Pauline Funchain tweet mediaPauline Funchain tweet media
English
1
2
16
972
Maysa Vilbert retweetledi
Meta Analysis Academy
Meta Analysis Academy@metaacademy_ofc·
From Rio de Janeiro to Boston, Cardiff to Kaliningrad, Recife to Madrid – this publication is a testament to the global connections made possible by the #metamasters. Yasmin Mesquita led a study published in the prestigious ‘Journal of the European Academy of Dermatology and Venereology’. Her analysis of nine studies highlighted confocal microscopy as a viable alternative to histopathology in #melanoma margin mapping.
Meta Analysis Academy tweet media
English
1
2
7
488
Maysa Vilbert retweetledi
Allison Betof, MD, PhD, FASCO
Allison Betof, MD, PhD, FASCO@DrBetofMDPhD·
Always an inspiration to hear Dr Stephanie Goff present on #TILs. We need to stop thinking about this as palliative therapy! TILs have the potential to CURE- complete responders from @theNCI with 10 year melanoma-specific survival of 96%. Unmodified TILs are just a starting point. Now, how do get MORE of our patients to a CR? #ImmunotherapyBridge24
Allison Betof, MD, PhD, FASCO tweet media
English
1
12
64
6.4K
Maysa Vilbert retweetledi
Daniel V. Araujo
Daniel V. Araujo@DVAraujoMD·
1/ I’m thrilled to share our study, “Low-Dose Anti-PD(L)1 for the Treatment of Solid Malignancies,” now published in @JCOGO_ASCO ! 🔗 ascopubs.org/doi/full/10.12… This study reflects the dedication and teamwork of everyone involved.
English
4
19
68
4.8K
Maysa Vilbert retweetledi
Jonathan N. Priantti
Jonathan N. Priantti@jpriantti·
So proud to share our work in @JCOPO_ASCO 🫁Our meta-analysis highlights the safety and efficacy of #osimertinib in patients with #NSCLC and uncommon #EGFR mutations. I’m really glad and honored to have this amazing international collaboration with this dream team.
Rafeh Naqash, MD, FASCO@thenasheffect

🚨⭐️ effort led by @jonathanpriantti @waraonc23 @MaysaVilbert out now in @JCOPO_ASCO on Efficacy of osimertinib in rare EGFR NSCLC. @EGFRResisters. Most comprehensive systematic review to date! @AminNassarMD @ACortelliniMD @JairBar4 @Alfdoc2 @LudiCa19862 ascopubs.org/doi/10.1200/PO…

English
0
1
5
297
Maysa Vilbert
Maysa Vilbert@MaysaVilbert·
Congratulations @isabfmichelon and @m_dacoregio_!👏 These findings are important in understanding the impact of ADCs in #HER2-low #MBC. Honored to be part of it! Kudos to all the amazing collaborators and mentors @LudiCa19862,@jpriantti,@LucasVian2, @PTarantinoMD, @E_de_Azambuja
Isabella Michelon@isabfmichelon

Proud to share our work in @TAMedOncol! Our meta-analysis of 2000+ patients with #HER2-low #MBC reveals a 50% reduction in the risk of progression/death with ADCs compared to chemo. #BCSM 🔗 full: journals.sagepub.com/doi/10.1177/17…

English
0
2
8
1.4K

Keşfet

@ASPIRE_CoP @IASLC @RamalingamMD @WinshipAtEmory @DukeCancer @DukeCancerNETWK @afreenshariffmd @FunchainMD